Early Clinical Study on Increasing Dose and Open Label of T Cell Injection Targeting CD7 Autologous Chimeric Antigen Receptor in the Treatment of Relapsed / Refractory CD7 Positive Hemolymph System Malignancies
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Anti-CD7 chimeric antigen receptor T-cell therapy-PersonGen Biomedicine (Primary)
- Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors PersonGen Biotherapeutics
- 04 Jan 2021 Status changed from not yet recruiting to recruiting.
- 24 Jul 2020 New trial record